ANDA 202825, held by Accord Hlthcare. Sertraline Hydrochloride.
As of Nov 16, 2026, ANDA 202825 (Sertraline Hydrochloride), held by Accord Hlthcare, was first approved by FDA on Nov 7, 2014, with 5 approved supplements and 0 published complete response letters.
Sertraline hydrochloride tablets are indicated for the treatment of the following: Major depressive disorder (MDD) Obsessive-compulsive disorder (OCD) Panic disorder (PD) Posttraumatic stress disorder (PTSD) Social anxiety disorder (SAD) Premenstrual dysphoric disorder (PMDD) Sertraline is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of: Major depressive disorder (MDD) Obsessive-compulsive disorder (OCD) Panic disorder (PD) Post-traumatic stress disorder (PTSD) Social anxiety disorder (SAD) Premenstrual dysphoric disorder (PMDD)
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 7, 2014 | Original application | Approved | None posted |
| Sertraline HydrochlorideEQ 25MG BASE · tablet;oral | Sertraline Hydrochloride | Rx |
| Sertraline HydrochlorideEQ 50MG BASE · tablet;oral | Sertraline Hydrochloride | Rx |
| Sertraline HydrochlorideEQ 100MG BASE · tablet;oral | Sertraline Hydrochloride | Rx |
| Nov 7, 2024 | Supplement 12Labeling · Standard review | Approved | None posted |
| Nov 7, 2024 | Supplement 11Labeling · Standard review | Approved | None posted |
| Nov 7, 2024 | Supplement 10Labeling · Standard review | Approved | None posted |
| May 8, 2018 | Supplement 2Labeling · Standard review | Approved | None posted |
| May 8, 2018 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 7, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters